@article{376f7135f24a4ccb8ae942a55a95f708,
title = "Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program",
abstract = "In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 sites. PHASER is staggering program initiation at sites over a 5-year period from 2019 to 2023, as opposed to simultaneous initiation at all sites, to facilitate iterative program quality improvements through Plan-Do-Study-Act cycles. Current resources in the PGx field have not focused on multisite, remote implementation of panel-based PGx testing. In addition to bringing large scale PGx testing to veterans, the PHASER program is developing a roadmap to maximize uptake and optimize the use of PGx to improve drug response outcomes. ",
keywords = "Veterans Affairs, clinical program, pharmacogenetics, pharmacogenomics, precision medicine, veterans",
author = "Dong, {Olivia M.} and Jill Bates and Catherine Chanfreau-Coffinier and Michael Naglich and Kelley, {Michael J.} and Meyer, {Laurence J.} and Michael Icardi and Vassy, {Jason L.} and Peruvemba Sriram and Heise, {Craig William} and Salvador Rivas and Maria Ribeiro and Russell Jacobitz and Susan Rozelle and Chapman, {Jennifer G.} and Deepak Voora",
note = "Funding Information: The PHASER program is funded through a $50 million dollar donation from Sanford Health and Denny Sanford. O. Dong was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number 5T32HG008955-03. D Voora is a member of the Sanford Health{\textquoteright}s Imagenetics External Advisory Board for which he receives an annual honorarium. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.. All rights reserved.",
year = "2021",
month = feb,
doi = "10.2217/pgs-2020-0173",
language = "English (US)",
volume = "22",
pages = "137--144",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "3",
}